companiesCompany
Evive Biotech
Evive Biotech developed efbemalenograstim alfa (Ryzneuta), a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the US in 2023 and the EU in 2024.
Overview
Evive Biotech (a Yifan Pharmaceutical company) developed efbemalenograstim alfa, a dimeric G-CSF-Fc fusion protein approved by the FDA in November 2023 and by the European Commission in March 2024 to reduce the duration of neutropenia and febrile neutropenia after myelosuppressive chemotherapy.
Headquarters
Shanghai, CN
Scorecard
All companies#146of 680 companies, score 14
- approved products +6
- modalities +2
- regions +2
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Type
biotech
Website